This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

Erratum

In the article "Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids" by Bryan R. Haugen, Lori Lee Larson, Umarani Pugazhenthi, William R. Hays, Joshua P. Klopper, Cynthia A. Kramer and Vibha Sharma (J Clin Endo Metab 89: 272–280, 2004), the authors recently confirmed to the best of their ability that BHP 5-16, BHP 14-9 and BHP 17-10 match the short tandem repeat (STR) profile of the NPA-87 cell line. This, in turn, matches the STR profile of the melanoma cell line M14. Therefore, the authors believe the BHP cell lines are actually sublines derived from the M14 melanoma cell line as described in the paper by Schweppe et al, "DNA Profiling Analysis of 38 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification," (J Clin Endo Metab 93: 4331–4341). Additionally, DRO-90 matches the STR profile of A375 and is believed to be a subline of this melanoma-derived cell line. MRO-87 matches the STR profile of ARO-81 (a cell line not addressed in this manuscript), which matches the profile of HT-29, a colon cancer cell line. Thus, MRO-87 likely represents a subline of the HT-29 colon cancer cell line. Finally, BHP 2-7, BHP 7-13 and BHP 10-3 have STR profiles that match the papillary thyroid cancer-derived cell line TPC-1. TAD-2 and WRO-82 are believed to be of thyroid cell origin, as described in the manuscript. The authors believe the results are relevant given that retinoid and rexinoid receptors are molecular targets for novel cancer therapies that have been described in many poorly differentiated carcinomas.

This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content